Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
CLDXCelldex Therapeutics(CLDX) Zacks Investment Research·2024-02-26 22:11

Celldex Therapeutics (CLDX) came out with a quarterly loss of 0.57pershareversustheZacksConsensusEstimateofalossof0.57 per share versus the Zacks Consensus Estimate of a loss of 0.76. This compares to loss of 0.56pershareayearago.Thesefiguresareadjustedfornonrecurringitems.Thisquarterlyreportrepresentsanearningssurpriseof250.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of 0.67 per share when it actually produced a loss of $0.81, delivering a surprise of -20.90%. Over the last four quarters, t ...